
1. Apoptosis and breast cancer
The clustering of death receptors (DRs) at the membrane leads to apoptosis.
2. Apoptosis and Colorectal cancer
Resistance to immunotherapy in colorectal cancer (CRC) is associated with obstruction of FAS (Apo‐1 or CD95)‐dependent apoptosis.
3. Apoptosis and bladder cancer
Molecular understanding of muscle-invasive (MIBC) and non–muscle-invasive (NMIBC) bladder cancer is currently based primarily on transcriptomic and genomic analyses.
4. Apoptosis and blood cancer
TP53-mutant blood cancers remain a clinical challenge. BH3-mimetic drugs inhibit BCL-2 pro-survival proteins, inducing cancer cell apoptosis.
References:
[1]Wang Y, Baars I, Berzina I, et al. A DNA robotic switch with regulated autonomous display of cytotoxic ligand nanopatterns. Nat Nanotechnol. 2024. doi:10.1038/s41565-024-01676-4. (IF=38.1)
[2]Ma H, Suleman M, Zhang F, et al. Pirin Inhibits FAS-Mediated Apoptosis to Support Colorectal Cancer Survival. Adv Sci (Weinh). 2024;11(10):e2301476. (IF=14.3)
[3]Groeneveld CS, Sanchez-Quiles V, Dufour F, et al. Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors. Eur Urol. 2024;85(5):483-494. (IF=25.3)
[4]Diepstraten ST, Yuan Y, La Marca JE, et al. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. Cancer Cell. 2024;42(5):850-868.e9. (IF=48.8)
